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Abstract
Background: Hepatitis C virus (HCV) is a significant global health concern. Despite evidence of the relationship
between injecting drug use and HCV, studies on HCV among people who inject drugs in developing countries
remain scarce. To address this need, we conducted this study to explore the prevalence of and factors associated
with HCV antibody positivity among people who inject drugs in Cambodia.
Methods: Data used for this study were collected as part of the National Integrated Biological and Behavioral
Survey among people who use and inject drugs conducted in 2017. We used the respondent-driven sampling
method to recruit participants in 12 provinces for face-to-face interviews and HIV and HCV antibody testing.
Weighted multivariable logistic regression analysis was conducted to identify risk factors associated with HCV
antibody positivity.
Results: This study included 286 people who inject drugs with a mean age of 31.6 (SD = 7.5) years. The prevalence of
HCV antibody among participants in this study was 30.4%, of whom 31.0% were co-infected with HIV. After adjustment
for other covariates, the odds of HCV antibody positivity was significantly higher among participants who were in the
older age group of 25 to 34 (AOR = 1.85, 95% CI = 1.06–7.92) and ≥ 35 (AOR = 2.67, 95% CI = 1.24–5.71), were in
Vietnamese ethnic group (AOR = 5.44, 95% CI = 2.25–13.14), were living on the streets (AOR = 3.01, 95% CI = 1.29–704),
had been sent to a drug rehabilitation center in the past 12 months (AOR = 2.67, 95% CI = 1.21–5.90), had received
methadone maintenance therapy in the past 12 months (AOR = 3.02, 95% CI = 1.32–6.92), and were tested positive for
HIV (AOR = 3.80, 95% CI = 1.58–9.12) compared to their respective reference group.
Conclusion: The prevalence of HCV antibody among people who inject drugs in Cambodia is high, particularly in
older and more vulnerable subgroups. Tailor-made interventions are required to increase access to culturally sensitive
harm reduction interventions to prevent primary HCV infection and reinfection. In addition, there is an opportunity to
expand screening, diagnosis, and treatment with new directly acting antiviral agents.
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Background
Hepatitis C is a significant global health problem [1].
The global prevalence of hepatitis C virus (HCV) is estimated at 3%, translating to at least 185 million people
living with the infection worldwide [2]. Persistent HCV
infection is a leading cause of hepatic cirrhosis, hepatocellular cancer, and liver failure [3]. In 2015, an estimated 495,000 deaths occurred worldwide attributable
to HCV [4]. Besides high mortality rates, HCV infection
is associated with significant healthcare costs [5].
While the global incidence patterns of HCV have
shifted significantly in recent years [2, 6], it has
remained a common health problem among people who
inject drugs (PWID) [6, 7]. In Cambodia, PWID are a
priority population for human immunodeficiency virus
(HIV) and harm reduction programming. However,
much of the current efforts relate to HIV prevention
and treatment among this population [8]. The current
focus on prevention and treatment of HIV among PWID
is reasonable given the very high HIV prevalence among
this group nationally, at 24.8% [9]. In this context, the
Cambodian Ministry of Health has set a goal to eliminate new HIV infection by 2025 through the implementation of the Cambodia 3.0 Strategy that focuses on key
populations such as PWID, female entertainment
workers, men who have sex with men, and transgender
women [10]. Consequently, a large part of the existing
strategic information related to PWID in Cambodia is
concerned with HIV, with relatively limited research
having been conducted on HCV epidemiology in this
population. While a limited number of studies on HCV
epidemiology have been conducted in Cambodia, those
studies have mostly focused on the general population
[11–13]. Where PWID have been included in these studies, their proportion was small [11].
Injecting drug use is a key driving factor for both
HCV and HIV, particularly when injecting is conducted
through shared equipment [14]. This situation calls for
increased focus on PWID. PWID infected with HCV
represent a high-risk group in terms of unsafe injecting
practices. Identifying those at high risk for HCV infection could inform education efforts for safer injection
among PWID who have not been reached by such services. Such efforts could also contribute to prevention of
co-infection with HIV among those already infected with
HCV. Early detection of HCV could lead to earlier treatment, given the increasing availability of better-tolerated
oral antiviral drugs [15, 16]. Currently, access and treatment to pegylated interferon and ribavirin is very limited
in Cambodia [11].
Given the health impacts of HCV infection, the potential for HCV/HIV co-infection, the national goal of better responding to the needs of key and vulnerable
populations, and the limited data related to HCV among
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PWID in resource-limited settings, we conducted a
study aiming to determine the prevalence and correlates
of HCV antibody positivity in this population in
Cambodia so as to inform services, policy, and future research programs.

Methods
Study design, sites, and participants

Data used for this study were obtained from the National Biological and Behavioral Survey (IBBS) conducted among people who use and inject drugs from
June to December 2017 in the capital city of Phnom
Penh and other 11 major provinces. The selection of the
study sites was based on a feasibility assessment conducted by the study team prior to the main study. These
12 study sites contained 21 operational districts with
high-burden of HIV and large population size of people
who use and inject drugs. PWID were defined as people
who have injected any types of illicit drugs, defined by
the Cambodian Law on Control of Drugs, in the past
12 months [17]. To be included in the study, an individual must (1) be at least 18 years old, (2) have a valid
study coupon, (3) have not participated in this survey,
(4) meet the definition of PWID, and (5) be able and
willing to provide a written informed consent to participate in the study.
Sample size and sampling procedures

The sample size was calculated for the parent study
based on an assumption that HIV prevalence would have
decreased by 20% between the national survey in 2012
and the current IBBS and the estimated PWID population size of 1300 [9]. An estimated HIV prevalence of
20% was used, with a margin error of 1.5%, a confidence
interval of 95%, a response rate of 90%, and a design effect of 1.5. The minimum required sample size for this
study was approximately 280. For the overall IBBS, the
sample size was stratified by study sites based on the estimated population size of people who use non-injecting
drugs (PWUD), and roughly 15% of the estimated
PWUD in each site were recruited. Data collection was
conducted in 21 locations (six locations in Phnom Penh
and 15 locations in the remaining provinces), determined based on the required sample size of PWUD in
each study site. Approximately 25.0% of the estimated
1068 PWID in Phnom Penh in 2016 [18] were recruited,
assuming that there would be no PWID in provinces
outside the capital city according to HIV programs reports. However, all PWID found in provinces were included in the study.
The respondent-driven sampling (RDS) method was
used to recruit study participants, and the Strengthening
the Reporting of Observational Studies in Epidemiology
for RDS Studies (STROBE-RDS) statement was followed

Yi et al. Harm Reduction Journal

(2019) 16:29

[19]. The RDS was implemented in five stages. First, eligible four seeds who were well connected to other
PWID or PWUD in each location were selected with
support from non-governmental organizations (NGOs)
working in the area. Second, after obtaining a written informed consent, a personal identification number (PIN)
was assigned to each seed to be enrolled as a participant.
Third, three coupons were given to each seed to refer
three additional PWID. For a successful referral, the seed
would receive US$2, and the seed was expected to extend to 3–6 “recruitment waves” in each site. Additional
seeds would be selected in case the enrolment has been
halted because all recruitment chains have “dried up”
(i.e., stopped recruiting) or the initial seeds did not recruit participants. Finally, recruited individuals were invited to become seeds and recruit other peers.
Data collection training

A data collection training was conducted for three days
for all data research team members. The contents of the
training included informed consent process, interview
techniques, confidentiality and privacy, and practices of
the questionnaire administration. The teams also reviewed
the study protocol and tools, so that all members would
be thoroughly familiar with them. A laboratory refresher
training was also provided to data collection teams responsible for HCV and HIV testing. Team leaders were
also encouraged to perform daily reviews with the team
members to review progress and communicate any issues
that may occur during the data collection.
Data collection procedures and tool
HCV and HIV test

Rapid serological tests for HCV antibody was performed
by a laboratory technician from Médecins Sans Frontières
(MSF) in Cambodia with capillary blood using OraQuick©
(OraSure Technologies, Inc., Bethlehem). OraQuick© is a
World Health Organization (WHO) pre-qualified HCV
rapid qualitative immunoassay screening test based on
detection of immunoglobulin G HCV antibody [20]. A
reactive test establishes that a person had been exposed to
HCV resulting in the generation of HCV antibodies. The
newly detected HCV antibody positive cases were followed
up by MSF for further management.
Rapid HIV testing was performed by a laboratory technician from the provincial health department using SD
Bioline HIV/Syphilis Duo test (Standard Diagnostic, Inc.,
Korea). The SD Bioline HIV/Syphilis Duo test is a WHO
pre-qualified solid-phase immunoassay for the qualitative detection of antibodies to all isotypes (IgG, IgM, and
IgA) specific to HIV-1/2 and/or Treponema pallidum
simultaneously [21]. A non HIV-reactive result establishes that an individual is not HIV-infected. A confirmatory test was conducted on site using HIV 1/2
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STAT-PAK® Assay (Chembio Diagnostic Systems, Inc.,
New York) for cases with an HIV reactive result from
the SD Bioline HIV/Syphilis Duo test, in keeping with
the national HIV testing guidelines. The HIV 1/2
STAT-PAK™ Assay is a rapid immunochromatographic
screening test for the detection of HIV 1/2 antibodies
[22]. Participants received their results verbally in a
post-test counseling session after the interview. New
HIV-positive cases were linked to a local NGO working
in the area. After completion of the data collection, participants received a gift for their time and transport
compensation, costing approximately US$5.
Questionnaire development and measures

A structured questionnaire was developed using standardized tools adapted from previous studies among
HIV key populations in Cambodia [9, 23–25]. The questionnaire was initially developed in English and then
translated into Khmer, the national language of
Cambodia. Back-translation was performed to ensure
that the “content and spirit” of every original item were
maintained. A validated workshop was conducted with
representatives of beneficiaries, communities, and key
stakeholders working on HIV and harm reduction in
Cambodia. The questionnaire was pretested with
ten PWID in Phnom Penh, who were later excluded
from the main study.
We collected socio-demographic information including age (continuous), gender, type of the community
(urban or rural), years of formal education attained
(continuous), average income in the past 6 months
(continuous), living situation, and employment status.
Information on drug use included types of illicit drugs,
frequency of use, and needle and syringe exchange practices in the past 3 months. Sexual behaviors included
number of partners and condom use with non-commercial and commercial partners (defined as a partner with
whom the participant had sex in exchange for money or
goods) in the past 3 months. Participants were also
asked about community-based HIV and harm reduction
services they had received in the past 6 months. Other
information included HIV testing, symptoms of sexually
transmitted infections (STIs) and care seeking behaviors
for the most recent symptoms, use of other substances
(tobacco and alcohol) in the past 3 months, as well as
experiences with drug rehabilitation and methadone
maintenance therapy in the past 12 months.
Data analyses

All analyses were estimated with sampling weights that
corrected for nonresponse and sampling design [26].
The prevalence of HCV antibody was calculated by dividing the total number of HCV antibody positive participants with the total number of participants tested.
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Results

Socio-demographic characteristics and behavioral variables of HCV antibody positive participants were compared to those of HCV antibody negative participants
using Chi-square test (or Fisher’s exact test for an
expected cell value of < 5) for categorical variables and
Student’s t test or Mann-Whitney U test for continuous
variables. Age, level of education, and income were
transformed into categorical variables. To identify independent risk factors for HCV antibody positivity, variables associated with HCV antibody positivity at a
significance level of p < 0.05 in bivariate analyses were
simultaneously included in a multivariable logistic
regression model. Because of their epidemiological importance, we included age, gender, level of education,
and income in the model regardless of the significance
level in bivariate analyses. STATA Version 12.0 for
Windows (Stata Corp, TX, USA) was used for the
analyses.

Prevalence of HCV

This study included 286 PWID with a mean age of 31.6
(SD = 7.5). The majority of PWID in the survey (72.0%)
were residing in Phnom Penh. Of the total, 30.4% were
tested positive for HCV antibody (95% CI = 25.3–36.0%).
Almost one-third (31.0%) of the HCV antibody positive
individuals were co-infected with HIV. All HCV antibody positive cases were found in Phnom Penh. Only
11.5% of the HCV antibody positive cases were aware of
their HCV infection status prior to the study, and five
had received HCV treatment.
Hepatitis C-related characteristics

As shown in Table 1, 21.3% of the study participants reported having been tested for HCV and 15.8% receiving
HCV education through drop-in centers or peer outreach workers in the past 12 months. Only 20.8%
perceived that their HCV risk was higher than that of
the general population.

Ethical considerations

This study was approved by the National Ethics Committee for Health Research (NECHR) of the Ministry of
Health, Cambodia (No. 193 NECHR). Privacy of the respondents was protected by having the data collected
in a private place and confidentiality ensured by removing all personal identifiers from the study documents.
Participants were fully informed about the risks and
benefits they may expect from their participation and
the voluntary nature of the study. A written informed
consent was obtained from each participant prior to the
data collection.

Socio-demographic characteristics

Table 2 shows that 92.0% of the participants were recruited from urban communities; 72.4% were male; and
20.4% were in Vietnamese ethnic group. Less than half
(40.2%) were married, and 57.3% had attained primary
education or lower. While 39.9% reported living with
their family or relatives, 26.9% were living on the streets.
The most common job was a laborer or farmer (37.1%),
and 12.9% were unemployed. The majority of the participants (78.7%) reported an average monthly income in

Table 1 Hepatitis C-related characteristics among HCV antibody positive and negative PWID
Hepatitis C-related characteristics

Total (n
= 286)

HCV antibody test result
Positive (n = 87)

Negative (n = 199)

n (%)

n (%)

n (%)

Tested for HCV in lifetime

61 (21.3)

28 (32.2)

33 (16.6)

Tested for HCV in the past 12 months (n = 61)

47 (77.0)

22 (78.6)

25 (75.8)

Diagnosed or told about having hepatitis C (n = 61)

16 (26.2)

10 (35.7)

6 (18.2)

Currently on hepatitis C treatment (n = 16)

8 (50.0)

5 (50.0)

3 (50.0)

Received education on hepatitis C in the past 12 months

45 (15.8)

17 (19.5)

28 (14.1)

Source of information on hepatitis C received last time
Peer educator/outreach worker

23 (50.0)

7 (41.2)

16 (55.2)

Drop-in center

27 (58.7)

13 (76.5)

14 (43.3)

59 (20.8)

24 (27.6)

35 (17.8)

Perceived HCV risk compared to the general population
Higher
About the same

75 (26.4)

21 (24.1)

64 (27.4)

Lower

32 (11.3)

6 (6.9)

26 (13.2)

Do not know

118 (41.5)

36 (41.4)

82 (41.6)

HCV hepatitis C virus, PWID people who inject drugs
Chi-square (or Fisher’s exact test when a cell count was smaller than 5) was used
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Table 2 Socio-demographic characteristics of HCV antibody positive and negative PWID
Socio-demographic characteristics

Total (n
= 286)

HCV antibody test result
Positive (n = 87)

Negative (n = 199)

n (%)

n (%)

n (%)

P valuea

Living in an urban community

263 (92.0)

87 (100.0)

176 (88.4)

< 0.001

Male gender

207 (72.4)

66 (75.9)

141 (70.9)

Age group
18–24

54 (18.9)

1 (1.1)

53 (26.6)

25–34

122 (42.7)

43 (49.4)

79 (39.7)

≥ 35

110 (38.5)

43 (49.4)

67 (33.7)

Ethnic group

< 0.001

Khmer

227 (79.6)

47 (54.0)

180 (90.9)

Vietnamese

58 (20.4)

40 (46.0)

18 (9.1)

114 (39.9)

30 (34.5)

84 (42.2)

Current marital status
Never married

0.44

Married

115 (40.2)

37 (42.5)

78 (39.2)

Widowed/divorced/separated

57 (19.9)

20 (23.0)

37 (18.6)

164 (57.3)

61 (70.1)

103 (51.8)

Level of formal education completed
Primary (0–6 years)

0.009

Secondary school (7–9 years)

68 (23.8)

17 (19.5)

51 (25.6)

High school or higher (≥ 10 years)

54 (18.9)

9 (10.3)

45 (22.6)

On the street (homeless)

77 (26.9)

47 (54.0)

30 (15.1)

With family or relatives at home

114 (39.9)

21 (24.1)

93 (46.7)

In own dwelling

52 (15.0)

8 (9.2)

44 (22.1)

Living arrangement

< 0.001

With friends

15 (5.2)

6 (6.9)

9 (4.5)

Other

28 (9.8)

5 (5.7)

23 (11.6)

37 (12.9)

11 (12.6)

26 (13.1)

Main occupation
Unemployed

0.41

Entertainment worker

30 (10.5)

7 (8.0)

23 (11.6)

Office worker

75 (26.2)

29 (33.3)

46 (23.1)

Laborer/farmer

106 (37.1)

28 (32.2)

78 (39.2)

Other

38 (13.3)

12 (13.8)

26 (13.1)

105 (36.7)

33 (37.9)

72 (36.2)

Average monthly income in the past 6 months (US$)
< 100

0.38
< 0.001

0.53

100–199

120 (42.0)

39 (44.8)

81 (40.7)

≥ 200

61 (21.3)

15 (17.2)

46 (23.1)

HCV hepatitis C virus, PWID people who inject drugs
a
Chi-square (or Fisher’s exact test when a cell count was smaller than 5) was used

the past 6 months of < US$200. A significantly higher
proportion of HCV antibody positive participants were
living in an urban community (100% vs. 88.4%), were in
the age group of ≥ 35 (49.4% vs. 33.7%), were in
Vietnamese ethnic group (46.0% vs. 9.1%), had attained
primary education or lower (70.1% vs. 51.8%), and lived
on the streets (54.0% vs. 15.1%) compared to that in
HCV antibody negative group.

Characteristics of substance use

As shown in Table 3, the median time since they started
injecting drugs was 49 months (IQR = 16–120). About
half (50.3%) reported “injection” as the method of their
first drug use and that they were firstly introduced to
drugs by their friends or colleagues (80.4%). Heroin was
the most commonly used drugs in the past 3 months
(61.9%), followed by methamphetamine (23.8%). About
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Table 3 Characteristics of substance use among HCV antibody positive and negative PWID
Substance use characteristics

Total
(n = 286)

HCV antibody test result
Positive (n = 87)

Negative (n = 199)

n (%)

n (%)

n (%)

P valuea

Median months using drugs (IQR)

49 (16–120)

96 (36–132)

36 (12–120)

< 0.001

Mode of first drug use—injecting

104 (50.3)

51 (58.6)

93 (46.7)

0.06

Injecting drugs in the past 3 months

250 (88.0)

84 (96.6)

166 (84.3)

0.003

156 (61.9)

67 (79.8)

89 (53.0)

< 0.001

Type of drugs most commonly used in the past 3 months
Heroin
Yama/ice (methamphetamine)

60 (23.8)

21 (25.0)

39 (23.2)

0.75

Ecstasy

9 (3.6)

0 (0.0)

9 (5.4)

0.27

Always used new syringes/needles in the past 3 months

112 (66.7)

27 (61.4)

85 (68.5)

0.54

Used needles/syringes used by someone else in the past 3 months

37 (21.6)

8 (18.2)

29 (22.8)

0.31

Having been sent to a drug rehabilitation center in the past 12 months

119 (41.6)

55 (63.2)

64 (32.2)

< 0.001

Having received methadone maintenance therapy in the past 12 months

125 (43.7)

68 (78.2)

57 (28.6)

< 0.001

Alcohol drinking ≥ 3 times per week

84 (29.4)

13 (14.9)

71 (35.7)

< 0.001

Binge drinking ≥ 3times per week (n = 171)

83 (48.5)

13 (36.1)

70 (51.9)

0.09

HCV hepatitis C virus, IQR interquartile range, PWID people who inject drugs
a
Chi-square (or Fisher’s exact test when a cell count was smaller than 5) was used for categorical variables and Mann-Whitney U test for continuous variables

two-thirds (66.7%) reported always using new syringes/
needles for drug injection, and 21.6% using needles or
syringes that had been used by someone else in the past
3 months. Less than half (41.6%) had been sent to a drug
rehabilitation center, and 43.7% had received methadone
maintenance therapy in the past 12 months. The use of
other substances was also common, with 29.4% reported
alcohol drinking at least three times per week; of them,
48.5% reported binge drinking (drinking at least five
units of alcohol on a typical day) on at least 3 days per
week in the past 3 months.
The median time of using drugs was significantly longer
in HCV antibody positive group compared to that in HCV
antibody negative group (96 months vs. 36 months). The
proportion of participants who reported injecting any kind
of drugs (96.6% vs. 84.3%) and injecting heroin (79.8% vs.
53.0%) in the past 3 months was higher in HCV antibody
positive group than in HCV antibody negative group. The
proportion of participants who reported having been sent
to a drug rehabilitation (63.3% vs. 33.2%) and having received methadone maintenance therapy (78.2% vs. 28.6%)
in the past 12 months was significantly higher in HCV
antibody positive group. A significantly lower proportion
of HCV antibody positive participants reported alcohol
drinking ≥ 3 times per week in the past 3 months (14.9%
vs. 35.7%).
Sexual behaviors

Table 4 shows that 95.1% of participants reported being sexually active in the past 3 months, with a median number of sex partners of 1.0 (IQR = 0.0–2.0).
Only 16.6% reported always using condoms, and

45.4% reported having sex when a partner was intoxicated in the past 3 months. Of those who reported
having sex with partners not in exchange for money
or gifts (n = 108), 8.3% reported always using condoms with the non-commercial partners in the past
3 months. Of the total respondents, 23.3% reported
having sex in exchange for money or goods in the
past 3 months, of whom 26.8% reported always using
condoms with the commercial partners in the past
3 months. Despite their substantial HIV risk, only
27.3% perceived that their HIV risk was higher compared to that of the general population. No significant
difference was found in comparison of sexual behaviors in HCV antibody positive and negative group
(Table 4).

Access to community-based HIV services

Table 5 shows that 68.9% of the study participants
reported having received some form of communitybased HIV services in the past 6 months. The services
included condom and lubricant distribution (71.5%),
HIV/syphilis testing (63.1%), HIV education (48.8%),
needle and syringe distribution (50.8%), methadone
maintenance therapy (43.7%), drop-in services (22.3%),
and legal support (5.4%). The proportion of participants
who reported having received needles and syringes from
community-based harm reduction programs (68.2% vs.
41.9%) and methadone maintenance therapy (78.2% vs.
28.6%) in the past 6 months was significantly higher in
HCV antibody positive group than in HCV antibody
negative group.
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Table 4 Sexual behaviors among HCV antibody positive and negative PWID
Sexual behaviors in the past 3 months

Had sexual intercourse

Total
(n = 286)

HCV antibody test result
Positive (n = 87)

Negative (n = 199)

n (%)

n (%)

n (%)

P valuea

272 (95.1)

84 (96.6)

188 (94.5)

0.56

Median number of sex partners (IQR)

1.0 (0.0–2.0)

1.0 (0.0–1.0)

1.0 (0.0–2.0)

0.48

Always used condom with any partner

29 (16.6)

6 (13.3)

23 (17.7)

0.50

Had sex when a partner was intoxicated

79 (45.4)

23 (51.1)

56 (43.4)

0.37

Had sex with partners not in exchange for money or gift

108 (61.7)

26 (57.8)

82 (63.1)

0.53

Always used condom with partners not in exchange for money or gift

9 (8.3)

2 (7.7)

7 (8.5)

0.89

Had sex in exchange for money or goods

41 (23.3)

6 (13.3)

35 (26.7)

0.07

Always used condom with partners in exchange for money or goods

11 (26.8)

1 (16.7)

10 (28.6)

Perceived HIV risk compared to the general population

0.48
0.48

Higher

78 (27.3)

28 (32.2)

50 (25.1)

About the same

96 (33.6)

28 (32.2)

68 (34.2)

Lower

33 (11.5)

7 (8.0)

26 (13.1)

Do not know

79 (27.6)

24 (27.6)

55 (27.6)

59 (20.8)

24 (27.6)

35 (17.8)

Perceived HIV risk compared to the general population
Higher
About the same

75 (26.4)

21 (24.1)

64 (27.4)

Lower

32 (11.3)

6 (6.9)

26 (13.2)

Do not know

118 (41.5)

36 (41.4)

82 (41.6)

HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range
a
Chi-square (or Fisher’s exact test when a cell count was smaller than 5) was used for categorical variables and Mann-Whitney U test for continuous variables

Factors associated with HCV antibody

Factors associated with HCV antibody positivity among
PWID in this study are shown in Table 6. After adjustment for other covariates, the odds of HCV antibody
positivity was significantly higher among participants
who were in the older age group of 25 to 34 (AOR =
1.85, 95% CI = 1.06–7.92) and ≥ 35 (AOR = 2.67, 95% CI
= 1.24–5.71), were in Vietnamese ethnic group (AOR =
5.44, 95% CI = 2.25–13.14), were living on the streets
(AOR = 3.01, 95% CI = 1.29–704), had been sent to a

drug rehabilitation center in the past 12 months (AOR
= 2.67, 95% CI = 1.21–5.90), had received methadone
maintenance therapy in the past 12 months (AOR =
3.02, 95% CI = 1.32–6.92), and were tested positive for
HIV (AOR = 3.80, 95% CI = 1.58–9.12) compared to
their respective reference group.

Discussion
Findings from this national survey show that the overall
prevalence of HCV antibody among PWID in Cambodia

Table 5 Access to community-based HIV and harm reduction services among HCV antibody positive and negative PWID
Access to community-based services in the past 6 months

Total (n = 286)

HCV antibody test result
Positive (n = 87)

Negative (n = 199)

n (%)

n (%)

n (%)

P valuea

Received community-based services

197 (68.9)

66 (75.9)

131 (65.8)

0.09

HIV education

63 (48.8)

18 (40.9)

45 (52.9)

0.20

Condom and lubricant distribution

93 (71.5)

33 (75.0)

60 (69.8)

0.53

Needle and syringe distribution

66 (50.8)

30 (68.2)

36 (41.9)

0.005

HIV/syphilis testing

82 (63.1)

30 (68.2)

52 (60.5)

0.39

Legal support

7 (5.4)

2 (4.5)

5 (5.8)

0.76

Drop-in services

29 (22.3)

6 (13.6)

23 (26.7)

0.09

Methadone maintenance therapy

125 (43.7)

68 (78.2)

57 (28.6)

< 0.001

HCV hepatitis C virus, HIV human immunodeficiency virus, PWID people who inject drugs, STI sexually transmitted infections
a
Chi-square (or Fisher’s exact test when a cell count was smaller than 5) was used
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Table 6 Factors associated with HCV antibody positivity among
PWID in multivariate logistic regression model
Variables in the final model

AOR (95% CI)

P value

Age group
< 25

Reference

25–34

1.85 (1.06–7.92)

0.009

≥ 35

2.67 (1.24–5.71)

0.001

Ethnic group
Khmer

Reference

Vietnamese

5.44 (2.25–13.14)

< 0.001

Living arrangement
With family or relatives

Reference

In the street (homeless)

3.01 (1.29–7.04)

0.01

In own dwelling

0.64 (0.20–2.03)

0.45

With friends

0.15 (0.46–10.07)

0.33

Having been sent to a drug
rehabilitation center in the
past 12 months
No

Reference

Yes

2.67 (1.21–5.90)

0.02

Having received methadone
maintenance therapy in the
past 12 months
No

Reference

Yes

3.02 (1.32–6.92)

0.009

HIV testing result
Negative

Reference

Positive

3.80 (1.58–9.12)

< 0.001

AOR adjusted odds ratio, CI confidence interval, HCV hepatitis C virus, HIV
human immunodeficiency virus, PWID people who inject drugs
Age, gender, marital status, education level, income, and variables associated
with HIV infection in the bivariate analyses at a level of p < 0.05 were
simultaneously included in the model

was 30.4%. Prior to this study, a few smaller studies in
the country had reported varying HCV antibody prevalence in the Cambodian general adult populations, ranging from 2.3 to 14.7% [27–30]. Among Cambodian
people living with HIV, previous studies reported a
prevalence between 5.3 and 10.5% [11–13]. Although
one of these studies included some PWID, the number
was small [11].
Our study is the first exclusively conducted among
PWID and shows very high prevalence of HCV antibody
in this population. However, in this study, confirmation
of active infection and genotyping data were not feasible
due to cost of HCV ribonucleic acid (RNA) testing, and
it was not part of the national IBBS protocol. The prevalence of active hepatitis C would be expected to be lower
than the proportion of people with HCV antibody [11].
However, the prevalence of HCV antibody still provides
important data related to the potential magnitude of

HCV infection and has implications for education, services, and policy in Cambodia. For instance, of the 87
participants who tested positive for HCV, only ten
(11.5%) were aware of their status prior to the study, of
which only five had received HCV treatment.
Multivariate results showed several factors associated with positive HCV antibody screening results.
After adjustment for potential confounding factors,
the odds of testing positive for HCV antibody was
significantly higher among PWID who were in the
older age group of 25 to 34 and ≥ 35, compared with
those aged ≤ 25. The association of older age with
higher odds of testing positive for HCV antibody is
similar to findings in previous studies ([31–34]. It is
plausible that, as PWID continue to inject, they have
more opportunities to acquire HCV, and indeed, duration of injection has been reported as independently
predictive of HCV antibody positivity [31, 32, 35] or
seroconversion [36].
Our study suggests that HCV antibody positivity was
three times more likely to be detected among participants
who were living on the streets compared to those living
with their family or relatives at home. Other studies have
shown that homelessness is predictive of both the likelihood to inject [37] and to using shared equipment [38].
On a practical level, this finding provides a useful way in
which to categorize profiles of HCV risk among PWID,
who were also identified as being at higher risk of HIV in
this national survey (Mburu M, Chhoun P, Navy Chann,
Tuot S, Mun P, and Yi S: Prevalence and risk factors for
HIV infection among people who injct drugs in
Cambodia: findings from a national survey, submitted). As
such, outreach services to homeless PWID will be essential for prevention of both HCV and HIV. This is particularly relevant given that 26.9% of the participants were
living on the streets. In addition, the prevalence of HCV
antibody was five times higher among participants of Vietnamese ethnic origin. Although ethnicity has been reported to be associated with HCV in other studies [39],
we suggest that this is likely to be a proxy indicator of
other structural risk behavioral or other risk factors, which
would need to be further investigated in our context.
In Cambodia, the national response toward people
who use and inject drugs has previously included sending users to a compulsory drug rehabilitation center,
which have generally been associated with poor health
outcomes [40, 41]. In China, a recent study also found
that having been sent to a compulsory drug rehabilitation center increased the odds of positive HCV antibody
[33]. While these findings do not necessarily point to
causation, they are generally consistent with assertions
that structural factors related to arrests and incarceration could promote risky injection and may lead to
HCV infection [31]. Indeed, studies from other countries
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such as Iran, the United Kingdom, and Australia have
shown that the odds of positive HCV infection are
higher among PWID with history of incarceration [35,
42, 43].
The association between positive HCV antibody and
methadone maintenance therapy is not consistent across
the literature. Although it was associated with the
increased odds of testing positive for HCV antibody in
our own and other studies [33, 35], this association may
not necessarily be causal. Indeed, several studies indicate
that opioid substitution treatment (OST) could be protective of HCV [44, 45]. However, OST could be an indication of longer-term drug use and dependency that
may lead to increased HCV risk.
Our observation that being infected with HIV tripled
the odds of being positive for HCV antibody is not necessarily surprising, given the most common shared
risk factor for both infections—unsafe injection. In
our sample, 21.6% reported using needles or syringes
that had been used by someone else in the past
3 months. Indeed, the endemic level of HCV among
the general population in Cambodia could be related
to the historical popularity—and to some extent, unsafe injecting practices in the country [46, 47]. Other
studies, such as from Canada and India, have also reported associations between HIV and HCV [48, 49].

Policy implications

These results provide critical information for programming and policy. First, there is a need to raise awareness of hepatitis C, so as to ensure that detection is
increased. Increasing awareness of HCV can also benefit HIV testing, prevention, and treatment [49].
Second, there is a need for increased governmental
focus on hepatitis C, with intent of increasing screening, diagnosis, and treatment. Currently, access to
pegylated interferon and ribavirin is limited in
Cambodia [11]. Poor availability of treatment is known
to be associated with poor health outcomes among
those with hepatitis C in many low- and middle-income countries [50]. As opposed to treatment with
pegylated interferon and ribavirin, however, the advent
of new generation direct-acting antiviral (DAA) that
are effective across different genotypes [51, 52] could
provide impetus for enhancing screening, diagnosis,
and treatment. Although, currently, there is no national program to target hepatitis C in Cambodia, MSF
has provided hepatitis C screening and treatment using
DAAs free of charge since 2016. Given the high prevalence of HCV in PWID, this high-risk population
should be the target for both prevention and treatment
programs in Cambodia. In this study, using the
respondent-driven sampling method, we could reach
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87 PWID living with HCV; 88.5% of them who were
not aware of their HCV antibody status prior to the
study would benefit from the close follow-up and linkage to care and treatment services provided by MSF.
Limitations of the study

In interpreting our findings, it should be borne in mind
that the design, recruitment, methods of data collection,
and sample profile could affect what are reported.
However, the study aimed to be representative as far as
possible by recruiting participants nationally. The crosssectional nature of this study only captures a snapshot
and may not provide valuable information regarding
spontaneous clearance of HCV, which is part of natural
history of the infection [53]. Personal sensitive data were
collected from the participants through a self-reported
questionnaire, which can be affected by social desirability bias as is the case in other studies of PWID [54]. In
addition, the HCV antibody prevalence data presented in
this paper were based on a rapid test, and did not represent current active HCV infection [55]. A recent review
of rapid diagnostics reported that OraQuick ADVANCE®
had higher sensitivity (98%, 95% CI 97–98%) compared
to the other oral brands (pooled sensitivity: 88%, 95% CI
84–92%) [56]. Nevertheless, other diagnostic methods
such as polymerase chain reaction (PCR)-based positivity are required to identify active hepatitis C, but was
not feasible in this large national survey. Despite this
limitation, the oral rapid screening could be a useful
strategy for screening PWID who are unaware of their
HCV status [57], in keeping with the global testing and
elimination targets [55]. This is particularly relevant in
Cambodia, given the high prevalence of HCV antibody
found in this study.

Conclusions
Hepatitis C is becoming an important health promotion
focus for PWID globally [58]. Understanding the epidemiology of HCV among this population, who are
already heavily burdened by HIV, will inform future prevention, care, and treatment of HCV or HCV/HIV
co-infection. In Cambodia, HCV/HIV co-epidemic is
poorly characterized [58], yet this has relevance for
PWID. This article presents findings from a national
survey in Cambodian PWID, showing the HCV antibody
prevalence of 30.4%. In addition, several important
factors including older age, homelessness, Vietnamese
ethnicity, having been sent to a drug rehabilitation center, having received methadone maintenance therapy,
and being infected with HIV were independently predictive of HCV infection. Given the health impact of
hepatitis C, these findings suggest a number of policy
and programmatic implications to promote health of
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PWID who are vulnerable to or infected with HCV in
resource-limited settings.
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